Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and ...

GLP-1 supplement makers claim that their products work similarly to weight loss injections like Ozempic. Here's what experts ...

Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or ...

Among 140 patients who underwent colonoscopy or a colonoscopy-plus-EGD, "inadequate bowel preparation" (stool retained in the ...

Agents like semaglutide show promise for treatment of substance use disorders. Inaccessibility of GLP-1 agonists due to high ...

Improvements in the Dermatology Life Quality Index score and hidradenitis suppurativa flares were seen in people who achieved ...

Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes.